Article
ZEB1 mediates invasion and chemoresistance of glioblastoma
Search Medline for
Authors
Published: | September 11, 2012 |
---|
Outline
Text
Despite intense efforts in basic research and clinical medicine, glioblastoma remains one of the most lethal types of cancer. In particular, tumor recurrence after surgical resection, aggressive chemotherapy, and targeted radiation remains an insurmountable obstacle. Recurrence has been attributed to residual cancer cells that re-initiate tumor growth after primary clinical intervention. Here, we provide new evidence that a subpopulation of invasive and chemoresistant cancer cells is maintained by the transcription factor ZEB1 (zinc finger E-box binding homeobox 1). ZEB1 is preferentially expressed in invasive glioblastoma cells, and its knockdown results in a dramatic reduction of tumor invasion as well as increased sensitivity to the chemotherapeutic agent Temozolomide (Temodar®, TMZ) in vitro and in vivo. By regulating both cell-cell adhesion, as well as expression of the chemoresistance-mediating enzyme MGMT (O-6-Methylguanine DNA Methyltransferase), this activator of epithelial-mesenchymal transition (EMT) links chemoresistance directly to brain tumor invasion. We further identify a novel pathway for the regulation of chemoresistance in glioma. Importantly, ZEB1 expression in glioblastoma patients correlates with tumor grade and is predictive of shorter survival and failure of chemotherapy. These results indicate that ZEB1 activation promotes invasion and protects glioblastoma cells from current therapeutic approaches. We thus identify ZEB1 as an important candidate molecule for glioblastoma recurrence, a potential marker of invasive tumor cells and a promising therapeutic target.